PL2640842T3 - Sposoby i kompozycje do indukowania odpowiedzi immunologicznej na EGFRVIII - Google Patents

Sposoby i kompozycje do indukowania odpowiedzi immunologicznej na EGFRVIII

Info

Publication number
PL2640842T3
PL2640842T3 PL11841347T PL11841347T PL2640842T3 PL 2640842 T3 PL2640842 T3 PL 2640842T3 PL 11841347 T PL11841347 T PL 11841347T PL 11841347 T PL11841347 T PL 11841347T PL 2640842 T3 PL2640842 T3 PL 2640842T3
Authority
PL
Poland
Prior art keywords
egfrviii
inducing
compositions
methods
immune response
Prior art date
Application number
PL11841347T
Other languages
English (en)
Inventor
Peter M. Lauer
Keith Bahjat
Original Assignee
Aduro Biotech, Inc.
Providence Health & Services-Oregon D/B/A Providence Portland Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aduro Biotech, Inc., Providence Health & Services-Oregon D/B/A Providence Portland Medical Center filed Critical Aduro Biotech, Inc.
Publication of PL2640842T3 publication Critical patent/PL2640842T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL11841347T 2010-11-17 2011-11-17 Sposoby i kompozycje do indukowania odpowiedzi immunologicznej na EGFRVIII PL2640842T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41485010P 2010-11-17 2010-11-17
EP11841347.5A EP2640842B1 (en) 2010-11-17 2011-11-17 Methods and compositions for inducing an immune response to egfrviii
PCT/US2011/061164 WO2012068360A1 (en) 2010-11-17 2011-11-17 Methods and compositions for inducing an immune response to egfrviii

Publications (1)

Publication Number Publication Date
PL2640842T3 true PL2640842T3 (pl) 2018-11-30

Family

ID=46084412

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11841347T PL2640842T3 (pl) 2010-11-17 2011-11-17 Sposoby i kompozycje do indukowania odpowiedzi immunologicznej na EGFRVIII

Country Status (16)

Country Link
US (3) US9200057B2 (pl)
EP (1) EP2640842B1 (pl)
JP (1) JP5998370B2 (pl)
CN (1) CN103415620B (pl)
CA (1) CA2818353A1 (pl)
CY (1) CY1120622T1 (pl)
DK (1) DK2640842T3 (pl)
ES (1) ES2684684T3 (pl)
HR (1) HRP20181343T1 (pl)
HU (1) HUE039747T2 (pl)
LT (1) LT2640842T (pl)
PL (1) PL2640842T3 (pl)
PT (1) PT2640842T (pl)
RS (1) RS57630B1 (pl)
SI (1) SI2640842T1 (pl)
WO (1) WO2012068360A1 (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HUE058896T2 (hu) 2010-10-01 2022-09-28 Modernatx Inc N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
HUE039747T2 (hu) * 2010-11-17 2019-02-28 Aduro Biotech Inc Eljárások és kompozíciók EGFRVIII-ra való immunválasz indukálására
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS62993B1 (sr) 2011-10-03 2022-03-31 Modernatx Inc Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
WO2013185052A1 (en) 2012-06-08 2013-12-12 Aduro Biotech Compostions and methods for cancer immunotherapy
JP2015534822A (ja) 2012-11-06 2015-12-07 アデュロ バイオテック，インコーポレイテッド 条件的弱毒化細菌種ならびにその調製法および使用法
EP4074834A1 (en) 2012-11-26 2022-10-19 ModernaTX, Inc. Terminally modified rna
MX361680B (es) 2012-12-13 2018-12-13 Aduro Biotech Inc Composiciones que comprenden dinucleótidos de purina cíclicos que tienen estereoquímicas definidas y métodos para su preparación y uso.
CN104955835B (zh) 2012-12-27 2020-04-17 艾杜罗生物科技公司 促进抗原序列的李斯特菌表达的信号肽融合配偶体以及其制备和使用方法
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP2992000B1 (en) 2013-05-03 2020-07-08 The Regents of The University of California Cyclic di-nucleotide induction of type i interferon
PL2996473T3 (pl) 2013-05-18 2020-06-01 Aduro Biotech, Inc. Kompozycje i sposoby aktywacji sygnałowania zależnego od „stymulatora genu interferonu”
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
MX2016004249A (es) 2013-10-03 2016-11-08 Moderna Therapeutics Inc Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad.
SG10202011841WA (en) * 2014-04-24 2021-01-28 Advaxis Inc Recombinant listeria vaccine strains and methods of producing the same
US10925945B2 (en) 2014-10-13 2021-02-23 Providence Health & Services-Oregon Bacterial vaccines deficient in the 2-C-methyl-D-erythritol-4-phosphate pathway and methods of preparation and use thereof
AU2015333632A1 (en) * 2014-10-14 2017-06-01 The Trustees Of The University Of Pennsylvania Combination therapy for use in cancer therapy
US10688166B2 (en) 2014-11-03 2020-06-23 Cerus Corporation Compositions and methods for improved car-T cell therapies
WO2016145102A1 (en) 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
MX2017013174A (es) * 2015-04-13 2018-04-11 Aduro Biotech Inc Fusiones de variante iii del receptor de factor de crecimiento epidermico-mesotelina y métodos para usar los mismos.
EP3283100A2 (en) 2015-04-13 2018-02-21 Aduro Biotech, Inc. Immunogenic fusion proteins for the treatment of cancer
US20160316247A1 (en) * 2015-04-27 2016-10-27 Ericsson Ab Program and device class entitlements in a media platform
MX2017015149A (es) * 2015-05-26 2018-03-28 Advaxis Inc Inmunoterapia personalizada basada en vectores de suministro y usos de esta.
EP3313975A4 (en) * 2015-06-24 2019-03-13 Advaxis, Inc. MANUFACTURING DEVICE AND METHOD FOR PERSONALIZED ADMINISTRATION OF VECTOR-BASED IMMUNOTHERAPY
PE20181535A1 (es) 2015-12-16 2018-09-26 Gritstone Oncology Inc Identificacion, fabricacion y uso de neoantigeno
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
EP3491009A4 (en) * 2016-08-01 2020-03-04 Aduro BioTech, Inc. PROTEIN EXPRESSION AMPLIFIER SEQUENCES AND USE THEREOF
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
JP7227237B2 (ja) 2017-10-10 2023-02-21 グリットストーン バイオ インコーポレイテッド ホットスポットを利用した新生抗原の特定
AU2018373154A1 (en) 2017-11-22 2020-07-02 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
WO2021014398A1 (en) * 2019-07-23 2021-01-28 University Of Rijeka Faculty Of Medicine Integrated human cytomegalovirus / glioblastoma vaccine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US5552284A (en) 1991-03-29 1996-09-03 Genentech, Inc. Detection of interleukin-8 receptors by nudeic acid hybridization
IT1262895B (it) 1992-03-02 1996-07-22 Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
US6379943B1 (en) 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
US5709999A (en) * 1994-08-12 1998-01-20 Myriad Genetics Inc. Linked breast and ovarian cancer susceptibility gene
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
DE69532767T2 (de) * 1994-11-28 2004-08-12 Thomas Jefferson University Peptid umfassend eine Sequenz aus einer Fusionsverbindungsstelle in einem mutierten EGF-Rezeptor vom Typ III
US5888530A (en) 1995-07-21 1999-03-30 The General Hospital Corporation Method of enhancing delivery of a pharmaceutical formulation
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
WO2002097044A2 (en) * 2001-05-25 2002-12-05 Thomas Jefferson University Alternative splice forms of proteins as basis for multiple therapeutic modalities
US7794728B2 (en) 2002-05-29 2010-09-14 The Regents Of The University Of California Attenuated Listeria spp. and methods for using the same
EP1575500A4 (en) 2002-07-12 2007-01-03 Univ Johns Hopkins MESOTHELIN VACCINE AND MODEL SYSTEMS
PT1592441E (pt) 2003-02-06 2012-05-21 Aduro Biotech Listeria atenuada relativamente à entrada em células não patogénicas, vacinas compreendendo a listeria e métodos para sua utilização
KR101173871B1 (ko) 2003-02-06 2012-08-16 앤저 테라퓨틱스 인코퍼레이티드 변형된 독립생존 미생물, 백신 조성물 및 그것의 사용방법
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
KR101399591B1 (ko) * 2005-11-02 2014-06-18 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 동시 화학요법 및 면역요법
WO2007117371A2 (en) 2006-03-01 2007-10-18 Anza Therapeutics, Inc. Engineered listeria and methods of use thereof
SI1991263T1 (sl) 2006-03-01 2015-03-31 Aduro Biotech Listeria spremenjena z inĹľeniringom ter postopki za njenjo uporabo
US8900816B2 (en) * 2007-07-19 2014-12-02 Duke University Assay for anti-EGFRvIII antibodies
CA2724649A1 (en) 2008-05-19 2009-11-26 Anza Therapeutics, Inc. Compositions comprising prfa* mutant listeria and methods of use thereof
KR20110045010A (ko) * 2008-07-24 2011-05-03 아두로 바이오테크 Ｃ형 간염의 치료를 위한 조성물 및 방법
TWI543767B (zh) * 2008-08-19 2016-08-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
HUE039747T2 (hu) * 2010-11-17 2019-02-28 Aduro Biotech Inc Eljárások és kompozíciók EGFRVIII-ra való immunválasz indukálására

Also Published As

Publication number Publication date
CN103415620A (zh) 2013-11-27
EP2640842A1 (en) 2013-09-25
JP2014504851A (ja) 2014-02-27
DK2640842T3 (en) 2018-08-13
CY1120622T1 (el) 2019-12-11
US20180021420A1 (en) 2018-01-25
LT2640842T (lt) 2018-09-10
EP2640842B1 (en) 2018-05-30
US9200057B2 (en) 2015-12-01
US20140037662A1 (en) 2014-02-06
HRP20181343T1 (hr) 2018-10-19
PT2640842T (pt) 2018-10-12
CN103415620B (zh) 2016-10-12
RS57630B1 (sr) 2018-11-30
JP5998370B2 (ja) 2016-09-28
CA2818353A1 (en) 2012-05-24
EP2640842A4 (en) 2014-04-09
SI2640842T1 (sl) 2018-09-28
WO2012068360A1 (en) 2012-05-24
HUE039747T2 (hu) 2019-02-28
US20160074491A1 (en) 2016-03-17
US9775891B2 (en) 2017-10-03
ES2684684T3 (es) 2018-10-04

Similar Documents

Publication Publication Date Title
HRP20181343T1 (hr) Postupci i pripravci za induciranje imunosnog odgovora na egfrviii
HK1256896A1 (zh) 用於實現多重cold-pcr的方法和組合物
EP2598120A4 (en) COMPOSITIONS AND METHODS FOR INDUCING IMMUNE TOLERANCE
IL271305B (en) Anti-ntb–a antibodies and related compositions and methods
ZA201307919B (en) Composition and method for enhancing an immune response
HK1199694A1 (zh) 益生菌組合物和方法
ZA201402734B (en) Collector compositions and methods of using the same
EP2637691A4 (en) MATERIALS AND METHOD FOR CONTROLLING AN IMMUNE RESPONSE TO AN EPITOP
EP2629742A4 (en) HAIR CARE COMPOSITIONS AND RELATED METHODS
EP2552202A4 (en) METHODS AND COMPOSITIONS FOR WEIGHT LOSS
EP2861719A4 (en) COMPOSITIONS AND METHODS FOR DECREASING AN IMMUNE RESPONSE
GB201113770D0 (en) Novel compositions and uses thereof
EP2424990A4 (en) COMPOSITIONS AND METHODS FOR ENHANCING SPECIFIC IMMUNE RESPONSES OF ANTIGEN
HK1173657A1 (zh) 免疫組合物和方法
HK1206970A1 (en) Antigenic compositions and methods
EP2555788A4 (en) METHOD AND COMPOSITIONS FOR THE PROTECTION AND REGENERATION OF THE HEART
HK1201451A1 (en) Compositions and methods
GB201018650D0 (en) Methods and compositions
ZA201308892B (en) Compositions and methods
EP2766357A4 (en) MESOBILIVERDINE COMPOSITIONS AND METHOD THEREFOR
EP2742139A4 (en) IMMUNOGENIC COMPOSITIONS AND ASSOCIATED METHODS
IL233873A (en) Methods for soaking up immune tolerance to organ transplants
GB201116340D0 (en) Compositions and methods
GB201018651D0 (en) Methods and compositions
GB201010083D0 (en) Compositions and methods